스마트 인슐린 펜 시장 규모, 점유율, 예측, 동향 분석 : 제품별, 커넥티비티별, 호환성별, 채널별 - 세계 예측(-2031년)

Smart Insulin Pens Market Size, Share, Forecast, & Trends Analysis by Product (Reusable, Disposable Prefilled, Cartridge) Connectivity (Bluetooth, NFC) Compatibility (Blood Glucose Monitor, CGM) Channel (Hospital, Retail, Online)-Global Forecast to 2031

The smart insulin pens market is projected to reach $776.5 million by 2031 at a CAGR of 11.2% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the smart insulin pens market is driven by the rising incidence of diabetes, growing preference for digital health solutions, technological advancements in smart insulin pens, an increase in demand for drug self-administration, and initiatives worldwide toward diabetes awareness. However, the high cost of smart insulin pens, along with the low availability of alternatives, are restraining the growth of this market.

Furthermore, the rising demand for remote monitoring and telemedicine, partnerships and collaborations among smart insulin pen manufacturers, expanding economies, and personalized diabetes management are expected to generate market growth opportunities. However, a lack of understanding about the use of smart insulin pens in developing nations and a preference for traditional insulin delivery techniques are major challenges in the smart insulin pens market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years. The key players operating in the smart insulin pens market are Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Medtronic plc (Ireland), Emperra GmbH E-Health Technologies (Germany), pendiq GmbH (Germany), Jiangsu Delfu medical device Co., Ltd (China), Tandem Diabetes Care, Inc. (U.S.), Ypsomed AG (Switzerland), and Bigfoot Biomedical, Inc. (U.S.).

Among all products covered in this report, in 2024, the insulin cartridges segment is expected to account for the largest share of 63.3% of the smart insulin pen market. High diabetes incidence worldwide and technological advancements in insulin delivery systems are supporting the segment's largest share. Insulin cartridges offer ease of use and comfort to the patients. These also help in reducing drug wastage and providing accurate insulin dosing.

Among all connectivity covered in this report, in 2024, the Bluetooth connectivity segment is expected to account for the major share of the smart insulin pens market. The largest share is attributed to ease of data sharing, high range of connectivity, its integration with CGM systems, and access to real-time data. These factors offer convenience and flexibility to the user, which results in consumer preference for Bluetooth-connected smart insulin devices over insulin pens.

Among all glucose monitor compatibilities covered in this report, in 2024, the blood glucose monitor (BGM)-compatible pens segment to dominate the smart insulin pens market. The low cost of blood glucose monitors, high accuracy in results, and point-in-time ability to monitor blood glucose levels are the factors attributed to the largest share of the segment. Moreover, technological advancements in the monitors and compatibility with different smart insulin pens also support the segment's large market share.

Among all purchase channels covered in this report, in 2024, the retail pharmacies segment is expected to account for the largest share of 49.2% of the smart insulin pens market. The availability of retail pharmacies in the vicinities, the availability of a diverse range of products, and the chance to inspect the product before making a purchase attract consumers towards retail pharmacies. Moreover, the trustworthiness of pharmacists helps consumers make confident purchase decisions.

An in-depth analysis of the geographical scenario of the smart insulin pens market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Among all the geographies studied in this report, in 2024, North America is expected to account for the largest share of 35% of the smart insulin pens market. The presence of key market players, high healthcare spending, high patient population, and ease of accessibility to technologically advanced devices support the large share of this regional market.

Scope of the Report:

Smart Insulin Pens Market Assessment-By Product

• Reusable Insulin Pens
• Disposable Prefilled Insulin Pens
• Insulin Cartridges
• Accessories

Note: Accessories include data transmitters & injector ports.

Smart Insulin Pens Market Assessment-By Connectivity

• Bluetooth Connectivity
• Near Field Communication (NFC) Connectivity

Smart Insulin Pens Market Assessment-By Glucose Monitor Compatibility

• Blood Glucose Monitor (BGM) Compatible Pens
• Continuous Glucose Monitor (CGM) Compatible Pens

Smart Insulin Pens Market Assessment-By Purchase Channel

• Purchase Channel
• Retail Pharmacies
• Online/E-commerce Platforms

Smart Insulin Pens Market Assessment-By Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Spain
  • Austria
  • Netherlands
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
• 2.3. Market Sizing and Forecasting
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Drivers
  • 4.2.1. Increasing Number of Diabetes Cases
  • 4.2.2. Increasing Preference for Digital Health Solutions
  • 4.2.3. Technological Advancements in Smart Insulin Pens
  • 4.2.4. Increasing Demand for Self-Administration of Drugs
  • 4.2.5. Increasing Diabetes Awareness Programs
• 4.3. Restraints
  • 4.3.1. High Cost of Smart Insulin Pens
  • 4.3.2. Availability of Alternatives to Smart Insulin Pens
• 4.4. Opportunities
  • 4.4.1. Growing Demand for Remote Monitoring and Telemedicine
  • 4.4.2. Partnerships and Collaborations by the Smart Insulin Pens Companies
  • 4.4.3. Emerging Economies
  • 4.4.4. Personalized Diabetes Management Program
• 4.5. Challenges
  • 4.5.1. Lack of Awareness Regarding the Use of Smart Insulin Pens in Developing Countries
  • 4.5.2. Preference for Traditional Insulin Delivery Methods
• 4.6. Trends
  • 4.6.1. Integration with Continuous Glucose Monitoring (CGM) Systems
• 4.7. Factor Analysis
• 4.8. Regulatory Analysis
• 4.9. Pricing Analysis
• 4.10. Parent/Adjacent Market Analysis
• 4.11. Porter's Five Forces Analysis

5. Smart Insulin Pens Market Assessment-by Product

• 5.1. Overview
• 5.2. Reusable Insulin Pens
• 5.3. Disposable Prefilled Insulin Pens
• 5.4. Insulin Cartridges
• 5.5. Accessories

6. Smart Insulin Pens Market Assessment-by Connectivity

• 6.1. Overview
• 6.2. Bluetooth Connectivity
• 6.3. Near Field Communication (NFC) Connectivity

7. Smart Insulin Pens Market Assessment-by Glucose Monitor Compatibility

• 7.1. Overview
• 7.2. Blood Glucose Monitors (BGMs) Compatible Pens
• 7.3. Continuous Glucose Monitors (CGMs) Compatible Pens

8. Smart Insulin Pens Market Assessment-by Purchase Channel

• 8.1. Overview
• 8.2. Hospital Pharmacies
• 8.3. Retail Pharmacies
• 8.4. Online/E-commerce Platforms

9. Smart Insulin Pens Market Assessment-by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. France
  • 9.3.3. U.K.
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Austria
  • 9.3.7. Netherlands
  • 9.3.8. Rest of Europe
• 9.4. Asia-Pacific
  • 9.4.1. Japan
  • 9.4.2. China
  • 9.4.3. India
  • 9.4.4. Australia
  • 9.4.5. South Korea
  • 9.4.6. Australia
  • 9.4.7. Rest of Asia-Pacific
• 9.5. Latin America
• 9.6. Middle East & Africa

10. Competition Analysis

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Competitive Dashboard
  • 10.4.1. Industry Leaders
  • 10.4.2. Market Differentiators
  • 10.4.3. Vanguards
  • 10.4.4. Emerging Companies
• 10.5. Market Share Analysis/Market Rankings of Key Players (2023)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

• 11.1. Novo Nordisk A/S
• 11.2. Eli Lilly and Company
• 11.3. Sanofi S.A.
• 11.4. Medtronic plc
• 11.5. Emperra GmbH E-Health Technologies
• 11.6. pendiq GmbH
• 11.7. Jiangsu Delfu medical device Co., Ltd
• 11.8. Tandem Diabetes Care, Inc.
• 11.9. Ypsomed AG
• 11.10. Bigfoot Biomedical, Inc.

(Note: SWOT analysis of the top 5 companies will be provided.)

12. Appendix

• 12.1. Available Customization
• 12.2. Related Reports